Nurix Therapeutics Inc (NRIX) USD0.001

Sell:$11.82Buy:$12.58$1.51 (14.21%)

Prices delayed by at least 15 minutes
Sell:$11.82
Buy:$12.58
Change:$1.51 (14.21%)
Prices delayed by at least 15 minutes
Sell:$11.82
Buy:$12.58
Change:$1.51 (14.21%)
Prices delayed by at least 15 minutes

Company Information

About this company

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Key people

Arthur T. Sands
President, Chief Executive Officer, Director
Hans van Houte
Chief Financial Officer
Gwenn M. Hansen
Chief Scientific Officer
Christine Ring
Chief Legal Officer, Chief Compliance Officer, Secretary
John Northcott
Chief Commercial Officer
Julia Paige Gregory
Independent Chairman of the Board
Roy D. Baynes
Independent Director
Anil Kapur
Independent Director
Lori A. Kunkel
Independent Director
David L. Lacey
Independent Director
Click to see more

Key facts

  • EPIC
    NRIX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US67080M1036
  • Market cap
    $810.38m
  • Employees
    286
  • Shares in issue
    76.24m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.